The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Final overall survival for CSLC 0501: Phase 3 study of adjuvant versus neoadjuvant chemotherapy with docetaxel combined carboplatin for resectable stageⅠB-ⅢA non-small cell lung cancer.
 
Xue-ning Yang
No Relationships to Disclose
 
Wenzhao Zhong
No Relationships to Disclose
 
Xiao-song Ben
No Relationships to Disclose
 
Gui-bin Qiao
No Relationships to Disclose
 
Qun Wang
No Relationships to Disclose
 
Chang-li Wang
No Relationships to Disclose
 
Hong-He Luo
No Relationships to Disclose
 
Zheng Wang
No Relationships to Disclose
 
Hong-Hong Yan
No Relationships to Disclose
 
Si-yang Liu
No Relationships to Disclose
 
Yi-Long Wu
Honoraria - AstraZeneca; Boehringer Ingelheim; Lilly; Pfizer; Roche; Sanofi
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Merck; Roche
Research Funding - Boehringer Ingelheim (Inst); Roche (Inst)